NFE2L2 and lung carcinoma: Tumours with genetic activation of NRF2 are resistant to all current anti-cancer therapies, including ICIs, and therefore most lung cancer patients with mutations in KEAP1, or the NRF2 encoding NFE2L2, will progress to second-line treatment strategies [32].